Haemonetics Statistics
Total Valuation
Haemonetics has a market cap or net worth of $3.51 billion. The enterprise value is $4.54 billion.
| Market Cap | 3.51B |
| Enterprise Value | 4.54B |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Haemonetics has 45.45 million shares outstanding. The number of shares has decreased by -6.66% in one year.
| Current Share Class | 45.45M |
| Shares Outstanding | 45.45M |
| Shares Change (YoY) | -6.66% |
| Shares Change (QoQ) | -1.62% |
| Owned by Insiders (%) | 1.26% |
| Owned by Institutions (%) | 98.97% |
| Float | 44.86M |
Valuation Ratios
The trailing PE ratio is 37.70 and the forward PE ratio is 14.81. Haemonetics's PEG ratio is 1.37.
| PE Ratio | 37.70 |
| Forward PE | 14.81 |
| PS Ratio | 2.63 |
| Forward PS | 2.51 |
| PB Ratio | 4.39 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 13.49 |
| P/OCF Ratio | 11.98 |
| PEG Ratio | 1.37 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.71, with an EV/FCF ratio of 17.44.
| EV / Earnings | 46.67 |
| EV / Sales | 3.40 |
| EV / EBITDA | 12.71 |
| EV / EBIT | 18.05 |
| EV / FCF | 17.44 |
Financial Position
The company has a current ratio of 2.95, with a Debt / Equity ratio of 1.60.
| Current Ratio | 2.95 |
| Quick Ratio | 1.64 |
| Debt / Equity | 1.60 |
| Debt / EBITDA | 3.47 |
| Debt / FCF | 4.89 |
| Interest Coverage | 13.03 |
Financial Efficiency
Return on equity (ROE) is 12.03% and return on invested capital (ROIC) is 10.63%.
| Return on Equity (ROE) | 12.03% |
| Return on Assets (ROA) | 6.49% |
| Return on Invested Capital (ROIC) | 10.63% |
| Return on Capital Employed (ROCE) | 11.90% |
| Weighted Average Cost of Capital (WACC) | 5.60% |
| Revenue Per Employee | $443,346 |
| Profits Per Employee | $32,339 |
| Employee Count | 3,009 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.61 |
Taxes
In the past 12 months, Haemonetics has paid $30.72 million in taxes.
| Income Tax | 30.72M |
| Effective Tax Rate | 24.00% |
Stock Price Statistics
The stock price has increased by +5.30% in the last 52 weeks. The beta is 0.54, so Haemonetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +5.30% |
| 50-Day Moving Average | 64.89 |
| 200-Day Moving Average | 64.32 |
| Relative Strength Index (RSI) | 65.28 |
| Average Volume (20 Days) | 1,066,837 |
Short Selling Information
The latest short interest is 3.01 million, so 6.63% of the outstanding shares have been sold short.
| Short Interest | 3.01M |
| Short Previous Month | 2.58M |
| Short % of Shares Out | 6.63% |
| Short % of Float | 6.72% |
| Short Ratio (days to cover) | 2.90 |
Income Statement
In the last 12 months, Haemonetics had revenue of $1.33 billion and earned $97.31 million in profits. Earnings per share was $2.05.
| Revenue | 1.33B |
| Gross Profit | 792.87M |
| Operating Income | 251.53M |
| Pretax Income | 128.03M |
| Net Income | 97.31M |
| EBITDA | 357.15M |
| EBIT | 251.53M |
| Earnings Per Share (EPS) | $2.05 |
Balance Sheet
The company has $246.26 million in cash and $1.27 billion in debt, giving a net cash position of -$1.03 billion or -$22.63 per share.
| Cash & Cash Equivalents | 246.26M |
| Total Debt | 1.27B |
| Net Cash | -1.03B |
| Net Cash Per Share | -$22.63 |
| Equity (Book Value) | 796.32M |
| Book Value Per Share | 17.60 |
| Working Capital | 552.28M |
Cash Flow
In the last 12 months, operating cash flow was $293.22 million and capital expenditures -$32.78 million, giving a free cash flow of $260.44 million.
| Operating Cash Flow | 293.22M |
| Capital Expenditures | -32.78M |
| Depreciation & Amortization | 105.62M |
| Net Borrowing | -6.25M |
| Free Cash Flow | 260.44M |
| FCF Per Share | $5.73 |
Margins
Gross margin is 59.43%, with operating and profit margins of 18.86% and 7.29%.
| Gross Margin | 59.43% |
| Operating Margin | 18.86% |
| Pretax Margin | 9.60% |
| Profit Margin | 7.29% |
| EBITDA Margin | 26.77% |
| EBIT Margin | 18.86% |
| FCF Margin | 19.52% |
Dividends & Yields
Haemonetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.65% |
| Shareholder Yield | 6.65% |
| Earnings Yield | 2.77% |
| FCF Yield | 7.41% |
Analyst Forecast
The average price target for Haemonetics is $85.20, which is 10.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $85.20 |
| Price Target Difference | 10.23% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 5.20% |
| EPS Growth Forecast (3Y) | 8.03% |
Stock Splits
The last stock split was on December 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Haemonetics has an Altman Z-Score of 2.51 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.51 |
| Piotroski F-Score | 6 |